A Phase III Study of Pafolacianine Injection (OTL38) for Intraoperative Imaging of Folate Receptor–Positive Ovarian Cancer (Study 006)
Journal of Clinical Oncology · 10.01.2023 · 41 (2) · 276-284
DOI: 10.1200/jco.22.00291 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.01.2023. Verfasst von Janos L Tanyi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Hospital of the University of Pennsylvania, Abramson Cancer Center, West Pavilion, Philadelphia, PA. Hauptthemen laut MEDLINE: Folate Receptor 1, Ovarian Neoplasms. Die Arbeit wurde bisher 174-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE The adjunctive use of intraoperative molecular imaging (IMI) is gaining acceptance as a potential means to improve outcomes for surgical resection of targetable tumors. This confirmatory study examined the use of pafolacianine for real-time detection of folate receptor–positive ovarian cancer. METHODS This phase III, open-label, 11-center study included subjects with known or suspected ovarian cancer, scheduled to undergo cytoreductive surgery. The objectives were to confirm safety and efficacy of pafolacianine (0.025 mg/kg IV), given ≥ 1 hour before intraoperative near-infrared imaging to detect macroscopic lesions not detected by palpation and normal white light. RESULTS From March 2018 through April 2020, 150 patients received a single infusion of pafolacianine (safety analysis set); 109 patients with folate receptor–positive ovarian cancer comprised the full analysis set for efficacy. In 33.0% of patients (95% CI, 24.3 to 42.7; P < .001), pafolacianine with near-infrared imaging identified additional cancer on tissue not planned for resection and not detected by white light assessment and palpation, exceeding the prespecified threshold of 10%. Among patients who underwent interval debulking surgery, the rate was 39.7% (95% CI, 27.0 to 53.4; P < .001). The sensitivity to detect ovarian cancer was 83%, and the patient false-positive rate was 24.8%. Investigators reported achieving complete R0 resection in 62.4% (68 of 109) of patients. Drug-related adverse events were reported by 30% of patients (45 of 150) and most commonly included nausea, vomiting, and abdominal pain. No drug-related serious adverse events or deaths were reported. CONCLUSION This phase III study of pafolacianine met its primary efficacy end point, identifying additional cancers not otherwise identified or planned for resection. Pafolacianine may offer an important real-time adjunct to current surgical approaches for ovarian cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Hospital of the University of Pennsylvania, Abramson Cancer Center, West Pavilion, Philadelphia, PA.
- Virginia Commonwealth University Health, Massey Cancer Center, Richmond, VA.
- University of Arizona Cancer Center, Tucson, AZ.
- Mayo Clinic Hospital-Phoenix, Phoenix, AZ.
- Karmanos Cancer Institute, Detroit, MI.
- Mayo Clinic-Rochester, Rochester, MI.
ORCID-Profile: Janos L Tanyi, Leslie M Randall, Carrie L Langstraat, Ernest S Han, Mark A Morgan, Matthew A Powell, Robert M Wenham
Förderung
- NCI NIH HHS
Zitieren
APA
Tanyi, J. L., Randall, L. M., Chambers, S. K., Butler, K. A., Winer, I. S., Langstraat, C. L., Han, E. S., Vahrmeijer, A. L., Chon, H. S., Morgan, M. A., Powell, M. A., Tseng, J. H., Lopez, A. S., & Wenham, R. M. (2023). A Phase III Study of Pafolacianine Injection (OTL38) for Intraoperative Imaging of Folate Receptor–Positive Ovarian Cancer (Study 006). Journal of Clinical Oncology, 41(2), 276-284. https://doi.org/10.1200/jco.22.00291
Vancouver
Tanyi JL, Randall LM, Chambers SK, Butler KA, Winer IS, Langstraat CL, et al. A Phase III Study of Pafolacianine Injection (OTL38) for Intraoperative Imaging of Folate Receptor–Positive Ovarian Cancer (Study 006). Journal of Clinical Oncology. 2023;41(2):276-284. doi:10.1200/jco.22.00291
BibTeX
@article{Tanyi2023,
author = {Tanyi, Janos L and Randall, Leslie M and Chambers, Setsuko K and Butler, Kristina A and Winer, Ira S and Langstraat, Carrie L and Han, Ernest S and Vahrmeijer, Alexander L and Chon, Hye Sook and Morgan, Mark A and Powell, Matthew A and Tseng, Jill H and Lopez, Alexis S and Wenham, Robert M},
title = {A Phase III Study of Pafolacianine Injection (OTL38) for Intraoperative Imaging of Folate Receptor–Positive Ovarian Cancer (Study 006)},
journal = {Journal of Clinical Oncology},
year = {2023},
volume = {41},
number = {2},
pages = {276--284},
doi = {10.1200/jco.22.00291}
}
EUVIMED